Skip to main content

Laura Batlle Masó

I am a biologist specialized in immunogenetics. My line of research is focused on the analysis of genetic data of pediatric patients with immunodeficiencies. The aim of my research is to expand the knowledge about immunodeficiencies and to explore new diagnostic and therapeutic approaches.

Institutions of which they are part

Predoctoral researcher
Infection and immunity in pediatric patients
Vall Hebron Institut de Recerca
Laura Batlle Masó

Laura Batlle Masó

Laura Batlle Masó

Institutions of which they are part

Predoctoral researcher
Infection and immunity in pediatric patients
Vall Hebron Institut de Recerca

I am a biologist specialized in immunogenetics. My line of research is focused on the analysis of genetic data of pediatric patients with immunodeficiencies. The aim of my research is to expand the knowledge about immunodeficiencies and to explore new diagnostic and therapeutic approaches.

I studied a BSc in Human Biology (2011-2015) and a MSc in Clinical Analysis (2015-2016) at Pompeu Fabra University. I did the master's thesis at Uppsala University (Sweden). After that, I stayed at the Institute of Evolutionary Biology in Barcelona, ​​where I specialized in the bioinformatics analysis of genomic data.

In 2017 I started my doctoral thesis at the Genomics Core Facility of Pompeu Fabra University, working on the genetic analysis of data from various sequencing technologies and collaborating with different national and international hospitals and research teams. In this line, in 2018 I did a training stay at Radboud University (Netherlands) to enhance my expertise on the interpretation of genomic analysis from a clinical point of view.

In 2021, I defended my doctoral thesis on the different genetic mechanisms underlying immunodeficiency from research, bioinformatics, and clinical points of view. After that, I joined the Pediatric Infectious Diseases and Immunodeficiencies Unit as a postdoctoral researcher.

Projects

Identification and functional characterization of structural variants in patients with inborn errors of immunity

IP: Roger Colobran Oriol
Collaborators: Romina Dieli Crimi, Aina Aguiló Cucurull, Laura Batlle Masó, Andrea Martín Nalda, Neus Castells Sarret
Funding agency: Instituto de Salud Carlos III
Funding: 208750
Reference: PI23/00161
Duration: 01/01/2024 - 31/12/2026

La interacción entre el error innato de la inmunidad y los trastornos sanguíneos: desentrañando los defectos inmunitarios detrás de las enfermedades hematológicas comunes

IP: Pere Soler Palacín
Collaborators: Laura Batlle Masó, Maria Cristina Díaz de Heredia Rubio, Roger Colobran Oriol, Thaïs Murciano Carrillo, Constantino Sábado Álvarez, Miriam Gonzalez Amores, Janire Perurena Prieto, Andrea Martín Nalda, Lucas Moreno Martín-Retortillo, Jacques Gabriel Rivière
Funding agency: Instituto de Salud Carlos III
Funding: 179993.75
Reference: AC23_2/00033
Duration: 01/01/2024 - 31/12/2026

Acreditació AGAUR grup d'infecció en el pacient pediàtric immunodeprimit

IP: Pere Soler Palacín
Collaborators: Antoni Soriano Arandes, Acreditació AGAUR grup d'infecció en el pacient pediàtric immunodeprimit, Acreditació AGAUR grup d'infecció en el pacient pediàtric immunodeprimit, Jorgina Vila Soler, Laura Batlle Masó, Natalia Ana Mendoza Palomar, Maria Espiau Guarner, Aurora Fernandez Polo, Núria Worner Tomasa, Laura Lopez Seguer, Miriam Gonzalez Amores, Acreditació AGAUR grup d'infecció en el pacient pediàtric immunodeprimit, Susana Melendo Perez, Sonia Rodriguez Tello, Andrea Martín Nalda, Claudia Broto Cortes, Marie Antoinette Frick, Jacques Gabriel Rivière
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 0.01
Reference: 2021 SGR 00441
Duration: 01/01/2022 - 30/06/2025

Ajuts Margarita Salas formació

IP: Pere Soler Palacín
Collaborators: Laura Batlle Masó, Laia Perez Lasarte
Funding agency: Ministerio de Universidades
Funding: 0.01
Reference: MIU/M_SALAS/2022/BATLLE
Duration: 01/01/2023 - 31/12/2024

Related news

So far, 240 volunteers have been recruited within all the centres set to join adolescents’ clinical trial (named HH3) to test the efficacy, tolerability, and safety of the BIMERVAX® COVID-19 vaccine in adolescents aged 12 to 17.

The results show that, in some patients with mutations in the X chromosome, the healthy gene is inactivated and the mutated gene manifests itself, which favors the onset of the disease.

The study, which is part of the European RECOMB project, is currently recruiting volunteers.

Related professionals

Marta Fabregat Fernandez

Marta Fabregat Fernandez

Shock, Organ Dysfunction and Resuscitation
Read more
Marc Massa Gomez

Marc Massa Gomez

Research technician
Pneumology
Read more
Laura Barbera Ferrando

Laura Barbera Ferrando

Research technician
Read more
Dinara Samarkanova

Dinara Samarkanova

Main researcher
Transfusional Medicine
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.